Leukemia

State of the Art Mini Review in 2001

Marrow vs peripheral blood: impact on transplant outcome

SJ Forman
State of the Art Mini Review01 May 2001
Abnormalities of the CEBP alpha transcription factor: a major target in acute myeloid leukemia

DG Tenen
State of the Art Mini Review01 May 2001
MDR modulation in acute myelogenous leukemia: is it dead?

JE Karp
State of the Art Mini Review01 May 2001
Prognostic factors in acute myelogenous leukemia

EH Estey
State of the Art Mini Review01 May 2001
Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia?

R Storb
State of the Art Mini Review01 May 2001
Management of patients refractory to platelet transfusion

CA Schiffer
State of the Art Mini Review01 May 2001
Introduction of Ernest Beutler, MD

MA Lichtman
State of the Art Mini Review01 May 2001
Potential for therapy with AML-derived dendritic cells

D Claxton
A Choudhury
State of the Art Mini Review01 May 2001
Small molecule mimics of hematopoietic growth factors: improving on Mother Nature?

K Kaushansky
State of the Art Mini Review01 May 2001
New agents for induction and postremission therapy of acute myeloid leukemia

RA Larson
State of the Art Mini Review01 May 2001
Uncertainties in the standard care of acute myelogenous leukemia

JM Rowe
State of the Art Mini Review01 May 2001
AML1/CBFβ transcription complex: its role in normal hematopoiesis and leukemia

JR Downing
State of the Art Mini Review01 May 2001
Who should be transplanted for AML?

FR Appelbaum
State of the Art Mini Review01 May 2001
The treatment of acute leukemia: past, present, and future

E Beutler
State of the Art Mini Review01 May 2001
Targeted AML therapy: new biologic paradigms and therapeutic opportunities

CL Willman
State of the Art Mini Review01 May 2001

Search

Advanced search

Quick links